Arkansas Center for Advancing Pediatric Therapeutics (ArCAPT)

项目总结 今天在美国对儿童进行的绝大多数研究并不包括儿童 居住在美国国立卫生研究院确定的24个符合IDEA资格的州/地区，如阿肯色州。因此，调查结果 可能不适用于携带最高疾病负担的相当大比例的儿童，例如 肥胖、糖尿病、早产儿、肺和神经发育障碍。未来的治疗和非 如果要改善这些儿童的健康状况，就必须向他们提供治疗试验。阿肯色州 儿童研究所(ACRI)准备立即解决儿童基金会的总体计划目标 IDEA声明儿科临床试验网络(ISPCTN)，从而努力缩小 生活在理想状态中的孩子。为此，我们成立了阿肯色州儿科发展中心 治疗公司(ArCAPT)。我们的努力将以以下中心假设为指导：ArCAPT将使 不同的婴幼儿、儿童和青少年群体参与精心设计、创新的 具有最高质量和科学价值的临床试验。我们将利用我们独特的患者基础， 智力资本和既定的机构间资源，以加强由 美国国立卫生研究院和其他得到支持的研究。我们建立了临床试验企业和儿科临床高级干部 调查人员将使我们能够探索个体发育、环境暴露和 四个高度优先领域的疾病：上呼吸道和下呼吸道疾病；肥胖症；神经发育和围产期疾病 和后天发育。我们的假设将通过执行三个具体目标来验证：1)链接 建立支持儿科临床试验的机构间和机构内资源。我们将成为合作伙伴 与阿肯色州儿童医院和阿肯色州大学医学科学研究所合作，扩大 儿科试验，解决种族和少数民族健康问题的影响以及 环境因素和疾病，因为它们与治疗终点有关。2)。提供受监督的 在研究和临床试验实施方面的专业发展。我们将保持和扩大我们的 现有的临床研究团队，通过高等医学教育培养新一代儿科临床研究人员 开展儿科临床试验中的素质教育。3)。打造最先进的临床试验平台 适用于婴幼儿、儿童和青少年。使用涉及多个儿科医生的跨学科团队 小组专家，我们将扩大临床研究，测试和验证新技术、工具和方法 用于评估种族/民族、个体发育、环境、疾病和治疗反应之间的联系。 这项提案的结果将通过系统地改善阿肯色州及其他地区儿童的健康 解决理想州人口独特的健康挑战。

PROJECT SUMMARY The vast majority of research conducted in children in the United States (US) today does not include children living in the 24 IDeA eligible states/territories identified by the NIH such as Arkansas. Consequently, findings may not be generalizable to a substantial proportion of children who carry the highest disease burdens such as obesity, diabetes, pre-maturity, lung and neurodevelopmental disorders. Future therapeutic and non- therapeutic trials must be available to these children if their health status is to be improved. Arkansas Children's Research Institute (ACRI) is prepared to immediately address the overarching program goals of the IDeA States Pediatric Clinical Trial Network (ISPCTN) and thereby, work to close the “clinical trial gap” for children living in IDeA states. To this end, we have formed the Arkansas Center for Advancing Pediatric Therapeutics (ArCAPT). Our efforts will be directed by the central hypothesis that ArCAPT will enable the participation of diverse groups of infants, children and adolescents in expertly designed, innovative clinical trials of the highest quality and scientific value. We will leverage our unique patient base, intellectual capital and established inter-institutional resources to enhance pediatric clinical trials funded by the NIH and other supported research. Our established clinical trial enterprise and cadre of senior pediatric clinical investigators will enable us to explore the impact and intersection of ontogeny, environmental exposure and disease in four high priority areas: upper and lower airway disease; obesity; neurodevelopment and pre-, peri- and postnatal development. Our hypothesis will be tested by executing three specific aims: 1) Link established inter- and intra-institutional resources supporting pediatric clinical trials. We will partner with Arkansas Children's Hospital and the University of Arkansas for Medical Sciences to increase the scope of pediatric trials, address the impact of racial and ethnic minority health issues and the intersection of environmental factors and disease as they relate to therapeutic endpoints. 2). Provide supervised professional development in research and clinical trial implementation. We will maintain and expand our existing clinical research teams and train the next generation of pediatric clinical researchers through high quality education in the conduct of pediatric clinical trials. 3). Create a state-of-the-art clinical trial platform for infants, children and adolescents. Using a cross-disciplinary team involving multiple pediatric subspecialists, we will expand clinical research and test and validate new technologies, tools and approaches for evaluating the interface between race/ethnicity, ontogeny, environment, disease and treatment response. The outcome of this proposal will improve the health of children of Arkansas and beyond by systematically addressing the unique health challenges of IDeA state populations.